Log in

Eyenovia Stock Forecast, Price & News

-0.05 (-1.56 %)
(As of 09/22/2020 12:00 AM ET)
Today's Range
Now: $3.15
50-Day Range
MA: $3.72
52-Week Range
Now: $3.15
Volume152,413 shs
Average Volume459,454 shs
Market Capitalization$64.69 million
P/E RatioN/A
Dividend YieldN/A
Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
Read More
Eyenovia logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.74 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EYEN



Sales & Book Value

Annual SalesN/A
Book Value$0.71 per share


Net Income$-21,160,000.00


Market Cap$64.69 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
-0.05 (-1.56 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EYEN News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Eyenovia (NASDAQ:EYEN) Frequently Asked Questions

How has Eyenovia's stock been impacted by COVID-19?

Eyenovia's stock was trading at $2.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EYEN shares have increased by 8.6% and is now trading at $3.15.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Eyenovia?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Eyenovia

When is Eyenovia's next earnings date?

Eyenovia is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Eyenovia

How were Eyenovia's earnings last quarter?

Eyenovia Inc (NASDAQ:EYEN) released its earnings results on Wednesday, August, 12th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.04.
View Eyenovia's earnings history

What price target have analysts set for EYEN?

4 equities research analysts have issued twelve-month price objectives for Eyenovia's shares. Their forecasts range from $7.00 to $19.00. On average, they anticipate Eyenovia's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 312.7% from the stock's current price.
View analysts' price targets for Eyenovia

Are investors shorting Eyenovia?

Eyenovia saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 214,800 shares, a decline of 51.9% from the August 15th total of 446,700 shares. Based on an average trading volume of 1,190,000 shares, the short-interest ratio is currently 0.2 days. Currently, 1.7% of the company's shares are sold short.
View Eyenovia's Short Interest

Who are some of Eyenovia's key competitors?

What other stocks do shareholders of Eyenovia own?

Who are Eyenovia's key executives?

Eyenovia's management team includes the following people:
  • Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer & Director (Age 46)
  • Ms. Jennifer Clasby, VP of Clinical Operations (Age 65)
  • Mr. Luke Clauson, VP of R&D (Age 40)
  • Mr. John P. Gandolfo, CFO & Sec. (Age 58)
  • Mr. Michael M. Rowe, VP of Marketing

When did Eyenovia IPO?

(EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ served as the underwriters for the IPO.

What is Eyenovia's stock symbol?

Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."

Who are Eyenovia's major shareholders?

Eyenovia's stock is owned by a variety of retail and institutional investors. Top institutional investors include Uniplan Investment Counsel Inc. (2.99%). Company insiders that own Eyenovia stock include Curt H Labelle, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev.
View institutional ownership trends for Eyenovia

Which major investors are selling Eyenovia stock?

EYEN stock was sold by a variety of institutional investors in the last quarter, including Uniplan Investment Counsel Inc..
View insider buying and selling activity for Eyenovia

How do I buy shares of Eyenovia?

Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eyenovia's stock price today?

One share of EYEN stock can currently be purchased for approximately $3.15.

How big of a company is Eyenovia?

Eyenovia has a market capitalization of $64.69 million. The company earns $-21,160,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

What is Eyenovia's official website?

The official website for Eyenovia is www.eyenoviabio.com.

How can I contact Eyenovia?

Eyenovia's mailing address is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.